Combination immunotherapy with interleukin‐2 surface‐modified tumor cell vaccine and programmed death receptor‐1 blockade against renal cell carcinoma

Immunotherapy may be an effective way to prevent postoperative recurrence of renal cell carcinoma. Streptavidin‐interleukin‐2 (SA‐IL‐2) surface‐modified tumor cell vaccine developed through our protein‐anchor technology could induce specific antitumor T‐cell responses, but this immunotherapy cannot...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xinji, Shi, Xiaojun, Li, Jinlong, Hu, Zhiming, Gao, Jimin, Wu, Shihao, Long, Zhaolin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317916/
https://www.ncbi.nlm.nih.gov/pubmed/30343514
http://dx.doi.org/10.1111/cas.13842

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317916/
https://www.ncbi.nlm.nih.gov/pubmed/30343514
http://dx.doi.org/10.1111/cas.13842

Ejemplares similares